Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

ORION B

ORNBV.HEFI0009014377NASDAQ HelsinkiFIEUR
Stock price
ORION B
Loading chart...

Coverage

Latest articles

U.S. FDA approves new indication for Orion-Bayer prostate cancer drug
8 Jun 2025, 20:27ORNBV.HENASDAQ Helsinki

Filings

Recent filings

FilingDate
Information on the AGM of Orion Corporat23 Mar 2004
Erkki Etola elected Vice Chairman of Ori23 Mar 2004
Orion Group 2003 Financial Statements13 Feb 2004
PROPOSALS BY THE BOARD OF DIRECTORS TO T13 Feb 2004
16,800 Orion A-shares converted into B-s12 Feb 2004
35,000 Orion A-shares converted into B-s6 Feb 2004
Orion distributes an additional dividend11 Dec 2003
Risto Kanerva appointed new President of8 Dec 2003
Search

Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).

  • Previous
  • 1
  • 2
  • Next
110,000 Orion A-shares converted into B-2 Dec 2003
Additional dividend of EUR 1.50 proposed20 Nov 2003
Orion Group Interim Report 1-9/20035 Nov 2003
EU approval granted for Stalevo, Orion's23 Oct 2003
  • Previous
  • 1
  • More pages
  • 89
  • 90
  • 91
  • More pages
  • 95
  • Next
Company
ORION B
ORNBV.HENASDAQ Helsinki
Website: Unavailable
Coverage
7
Filings
1,130